Presentation is loading. Please wait.

Presentation is loading. Please wait.

Myron S. Cohen, MD Associate Vice Chancellor Director, Institute for Global Health The University of North Carolina.

Published byJacob McCarthy Modified over 8 years ago

Similar presentations

Presentation on theme: "Myron S. Cohen, MD Associate Vice Chancellor Director, Institute for Global Health The University of North Carolina."— Presentation transcript:

1 Myron S. Cohen, MD Associate Vice Chancellor Director, Institute for Global Health The University of North Carolina

2 Essential New Technologies HIV Incidence -An algorithm (HPTN 043) -CDC -IgG3 Point of Care Viral Load -Alere -Others

3 Four HIV Prevention Opportunities YEARS Treatment Of HIV Reduced Infectivity INFECTED YEARS UNEXPOSED Behavioral, Structural Circumcision Condoms STIs Cohen et al, JCI, 2008 Cohen IAS 2008 HOURS Vaccines ART PrEP Microbicides EXPOSED (precoital/coital) 72h Vaccines ART PEP EXPOSED (postcoital)

4 HPTN 052: What’s Next The HPTN 052 Cohort July 2012 1682/1763 index cases (96% retention) 1502 discordant couples (85% retention) DURABILITY OF PREVENTION? DELAYED CLINICAL EVENTS?

5 The “Test and Treat” Movement Granich et al. Current Opinion in HIV, 2011 More than 50 studies described!! US HPTN 065 Linkage in NYC, DC ANRS/Africa Center-South Africa THE PEPFAR Combination Prevention Trials: – CDC- BOTSWANA – NIH HPTN 071 -South Africa, Zambia – USAID JHU-Tanzania

6 HPTN 071 Intervention Package Community HIV Care Providers (CHiPs team): Counselling, condom provision, syndromic STI Rx Referral of pregnant women for ANC/PMTCT services Universal voluntary HIV testing house-to-house HIV-uninfected men offered circumcision HIV-infected persons −Arm A: Immediate ART (analogous to HPTN 052) −Arm B: “Enhanced” Standard of Care (CD4<350) −Arm C: Standard of Care (CD4<350)

7 10 -5 10 -4 10 -3 10 -2 10 -1 0 10 1 10 2 10 3 10 4 10 5 10 6 10 7 10 8 Transmission Virus Concentration in Extracellular Fluid or Plasma (Copies/ml) Time Post Exposure (days) 0510152030352540 455055606570 Reservoir Virus dissemination Transit eclipse ? T0T0 Acute Phase Reactants Days -5 to-7 Immune Complexes Day 9 Onset cytokines apoptosis, Day 7 Free Antibody, Day 13 CD8 T Cell Responses CTL Escape Autologous Neutralizing Antibody Autologous Neutralizing Antibody Escape Acute HIV-1 Infection: A Challenge Cohen et al, NEJM, 2011

8 The Next PrEP/Microbicides Do the results increase adherence: iPREX OLE? Can Truvada schedule change (HPTN 066,067) Can Maraviroc be used as PrEP (HPTN 069) Other oral agents? Other topical agents The Ring Can injectable agents be developed as PrEP

9 Can We Cure AIDS?

10 To be published 26 July 2012 Available on-line 1 PM 25 July 2012

Download ppt "Myron S. Cohen, MD Associate Vice Chancellor Director, Institute for Global Health The University of North Carolina."

Similar presentations

Antiretroviral Therapy: An HIV Prevention Strategy? Wafaa El-Sadr, MD, MPH Columbia University Harlem Hospital New York.

Antiretroviral Therapy: An HIV Prevention Strategy? Wafaa El-Sadr, MD, MPH Columbia University Harlem Hospital New York.
No one left behind: Increased coverage, better programmes and maximum impact for key populations WHO Consolidated Guidelines on HIV Prevention, Diagnosis,

No one left behind: Increased coverage, better programmes and maximum impact for key populations WHO Consolidated Guidelines on HIV Prevention, Diagnosis,
Women and ARV-based Prevention: Challenges and Opportunities Tim Mastro, MD, DTM&H AIDS 2014 Melbourne, Australia 24 July 2014.

Women and ARV-based Prevention: Challenges and Opportunities Tim Mastro, MD, DTM&H AIDS 2014 Melbourne, Australia 24 July 2014.
NATIONAL INSTITUTES OF HEALTH: National Institute of Allergy and Infectious Diseases National Institute of Mental Health National Institute on Drug Abuse.

NATIONAL INSTITUTES OF HEALTH: National Institute of Allergy and Infectious Diseases National Institute of Mental Health National Institute on Drug Abuse.
Monica Gandhi MD, MPH Associate Professor and Women’s HIV Clinic provider, HIV/AIDS Division San Francisco General Hospital/ UCSF Safe Poz Love, U.S. Positive.

Monica Gandhi MD, MPH Associate Professor and Women’s HIV Clinic provider, HIV/AIDS Division San Francisco General Hospital/ UCSF Safe Poz Love, U.S. Positive.
From “What If” to “What Now” Perspectives on ARVs and the Future of Treatment and Prevention Mitchell Warren Executive Director, AVAC IAS 2011, Rome.

From “What If” to “What Now” Perspectives on ARVs and the Future of Treatment and Prevention Mitchell Warren Executive Director, AVAC IAS 2011, Rome.
Treatment of HIV Stops Transmission : Where DO We Go From Here? Cohen et al Lancet, Nov. 2013 Myron S. Cohen, MD Yergan-Bate Professor Medicine, Microbiology.

Treatment of HIV Stops Transmission : Where DO We Go From Here? Cohen et al Lancet, Nov Myron S. Cohen, MD Yergan-Bate Professor Medicine, Microbiology.
PREVENTION OF HIV-1 Myron S. Cohen, MD Institute for Global Health The University of North Carolina.

PREVENTION OF HIV-1 Myron S. Cohen, MD Institute for Global Health The University of North Carolina.
Maurice Cook ( EM Designs Group, Inc.) The End of AIDS Transmission? Robert M Grant, June 2012.

Maurice Cook ( EM Designs Group, Inc.) The End of AIDS Transmission? Robert M Grant, June 2012.
HIV in Texas: The Ways Forward Ann Robbins Manager of HIV/STD Prevention and Care Department of State Health Services.

HIV in Texas: The Ways Forward Ann Robbins Manager of HIV/STD Prevention and Care Department of State Health Services.
Does Africa need a rectal microbicide? IRMA and AVAC presentation 27 September 2011 Salim S. Abdool Karim Pro Vice-Chancellor (Research), University of.

Does Africa need a rectal microbicide? IRMA and AVAC presentation 27 September 2011 Salim S. Abdool Karim Pro Vice-Chancellor (Research), University of.
HIV Prevention Biomedical A New Landmark in the Field of HIV Treatment

HIV Prevention Biomedical A New Landmark in the Field of HIV Treatment
TasP is not enough Stipulated that TasP is effective in reducing infectiousness of the treated person – But much more is required. TasP requires effective.

TasP is not enough Stipulated that TasP is effective in reducing infectiousness of the treated person – But much more is required. TasP requires effective.
INA-RESPOND Test and Treat Study

INA-RESPOND Test and Treat Study
Accelerating Anti-Retroviral Treatment as a catalytic action for Ending AIDS Pride Chigwedere, MD, PhD Senior Advisor to the African Union AWA CONSULTATIVE.

Accelerating Anti-Retroviral Treatment as a catalytic action for Ending AIDS Pride Chigwedere, MD, PhD Senior Advisor to the African Union AWA CONSULTATIVE.
How well are we doing in preventing HIV and how can we do better?

How well are we doing in preventing HIV and how can we do better?
Centers for Disease Control and Prevention Global AIDS Program Prevention Interventions for People Living with HIV: 5 HIV Prevention Steps and Tools for.

Centers for Disease Control and Prevention Global AIDS Program Prevention Interventions for People Living with HIV: 5 HIV Prevention Steps and Tools for.
Epidemiology of HIV and Access to Prevention services, Tanzania Joint Biennial HIV National Response Review Stakeholders meeting. November, 2014 Blue Pearl.

Epidemiology of HIV and Access to Prevention services, Tanzania Joint Biennial HIV National Response Review Stakeholders meeting. November, 2014 Blue Pearl.
HIV Science Update: From Rome to Addis – Biomedical Prevention Elly T Katabira, FRCP Department of Medicine Makerere University College of Health Sciences.

HIV Science Update: From Rome to Addis – Biomedical Prevention Elly T Katabira, FRCP Department of Medicine Makerere University College of Health Sciences.
Are people living with HIV less likely to pass HIV to others if they are on treatment? Exploring the use of treatment as prevention James Wilton Project.

Are people living with HIV less likely to pass HIV to others if they are on treatment? Exploring the use of treatment as prevention James Wilton Project.

Similar presentations

Ads by Google